Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice
Published 2010 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice
Authors
Keywords
-
Journal
JOURNAL OF CLINICAL INVESTIGATION
Volume 120, Issue 11, Pages 3953-3968
Publisher
American Society for Clinical Investigation
Online
2010-11-01
DOI
10.1172/jci43490
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2
- (2010) Jennifer L. Spratlin et al. JOURNAL OF CLINICAL ONCOLOGY
- Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen
- (2009) L. A. Johnson et al. BLOOD
- Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis
- (2009) Marta Pàez-Ribes et al. CANCER CELL
- VEGFR2 is selectively expressed by FOXP3high CD4+ Treg
- (2009) Hiroyuki Suzuki et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- An Anti-Vascular Endothelial Growth Factor Receptor 2/Fetal Liver Kinase-1 Listeria monocytogenes Anti-Angiogenesis Cancer Vaccine for the Treatment of Primary and Metastatic Her-2/neu+ Breast Tumors in a Mouse Model
- (2009) M. M. Seavey et al. JOURNAL OF IMMUNOLOGY
- A Herceptin-Based Chimeric Antigen Receptor with Modified Signaling Domains Leads to Enhanced Survival of Transduced T Lymphocytes and Antitumor Activity
- (2009) Y. Zhao et al. JOURNAL OF IMMUNOLOGY
- Construction and Preclinical Evaluation of an Anti-CD19 Chimeric Antigen Receptor
- (2009) James N. Kochenderfer et al. JOURNAL OF IMMUNOTHERAPY
- Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo
- (2009) Michael C. Milone et al. MOLECULAR THERAPY
- Chimeric Antigen Receptors Combining 4-1BB and CD28 Signaling Domains Augment PI3kinase/AKT/Bcl-XL Activation and CD8+ T Cell–mediated Tumor Eradication
- (2009) Xiao-Song Zhong et al. MOLECULAR THERAPY
- Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains
- (2009) C. Carpenito et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells
- (2008) B. G. Till et al. BLOOD
- IFN-γ– and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers
- (2008) Bin Zhang et al. JOURNAL OF CLINICAL INVESTIGATION
- Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens
- (2008) Mark E. Dudley et al. JOURNAL OF CLINICAL ONCOLOGY
- Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma
- (2008) Martin A Pule et al. NATURE MEDICINE
- UpGene: Application of a Web-Based DNA Codon Optimization Algorithm
- (2004) Wentao Gao et al. BIOTECHNOLOGY PROGRESS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started